Olaparib poly ADP-ribose polymerase (PARP) inhibitor

Description Results NMA

PFS 0.58 [0.43; 0.79] Demonstrated

OS 0.90 [0.63; 1.29]

Olaparib (Olaparib tablet 300mg bd po) (n=205)

vs.

Physician's choice chemotherapy (Capecitabine 2500 mg/m2 d1-14 q 21, or Vinorelbine 30 mg/m2 d1,8 q 21, or Eribulin 1.4 mg/m2 d1,8 q 21) (n=97)

open label

Sample size: 205/97

Primary endpoint: Progression Free Survival

FU duration: 14.5 months

PFS 0.35 [0.25; 0.49] median 8.4 mo vs. 4.8 mo

OS 0.94 [0.63; 1.40]

PFS 0.30 [0.22; 0.41] median 19.1 months vs. 5.5 months

olaparib, at a dose of 400 mg twice daily (n=136)

vs.

placebo (n=129)

double-blind

Sample size: 136/129

Primary endpoint:

FU duration:

phase 2

olaparib 300 mg in two 150 mg tablets, twice daily (n=196)

vs.

placebo (n=99)

double-blind

Sample size: 196/99

Primary endpoint: investigator-assessed progression-free survival

FU duration: